Coronary calcium scoring and coronary CT angiography are often discussed as though one is simply a more advanced version of the other. They actually answer different questions. A coronary artery calcium score is a well-established, non-contrast CT study that measures calcified plaque and helps refine long-term cardiovascular risk. A score of zero is reassuring, particularly in someone without major risk factors, but it does not prove that the coronary arteries are free of atherosclerosis because noncalcified plaque is invisible to a calcium scan.
Coronary CT angiography, or CCTA, uses intravenous contrast to visualize the coronary arteries, including plaque that has not calcified and areas where plaque is narrowing the vessel. When we use CCTA with Cleerly® Plaque Analysis, the study also provides quantitative information about total plaque burden, calcified and noncalcified plaque, low-density noncalcified plaque, and stenosis throughout the coronary tree.
We still use coronary calcium scoring when it is the right test. For patients in whom we need to understand the coronary disease itself rather than estimate risk from calcification alone, CCTA with quantitative plaque analysis provides a different level of information.
Coronary artery calcium scoring has been one of the most useful additions to preventive cardiology over the past several decades. It is relatively inexpensive, does not require intravenous contrast, involves a modest amount of radiation, and has an extensive evidence base linking coronary calcium burden with future cardiovascular risk.
We continue to use it. The limitation is not that calcium scoring is outdated or unimportant. The limitation is simply that it measures calcium, while coronary atherosclerosis consists of considerably more than calcium.
This becomes particularly relevant when a patient's laboratory testing, family history, symptoms, metabolic risk, or other cardiovascular findings do not seem to fit comfortably with the calcium score. In those situations, coronary CT angiography (CCTA) may provide information that cannot be obtained from CAC alone. When CCTA is combined with Cleerly® Plaque Analysis, we also receive quantitative measurements of the plaque present throughout the coronary arteries.
What a Coronary Calcium Score Measures
A coronary artery calcium score, or CAC score, is obtained from a CT scan performed without intravenous contrast. The scan detects calcium within atherosclerotic plaque in the coronary arteries and generally reports the result as an Agatston score.
Commonly used categories are:
- 0: no detectable coronary calcium
- 1–99: mild coronary calcification
- 100–399: moderate coronary calcification
- 400 or greater: extensive coronary calcification
These categories are useful, but the number is only part of the interpretation. Age, sex, blood pressure, smoking history, diabetes, family history, ApoB, lipoprotein(a), metabolic health, and other cardiovascular risk factors influence what a particular score means for an individual patient.
CAC is especially useful because the presence of coronary calcium confirms coronary atherosclerosis. As the amount of coronary calcium increases, cardiovascular risk generally increases as well. For someone whose preventive treatment remains uncertain after conventional risk assessment, finding coronary calcium may materially change that discussion.
Calcified plaque should not be dismissed as harmless or described simply as old plaque. A high calcium score represents a substantial accumulated burden of coronary atherosclerosis and carries important prognostic information.
What a Calcium Score Does Not Measure
Atherosclerosis develops within the arterial wall and may contain lipid, fibrous tissue, inflammatory material, calcium, or a combination of these components. Calcium often becomes more prominent as coronary disease evolves, but plaque does not have to be calcified to be present or clinically important.
A calcium scan therefore provides an incomplete anatomical picture of the coronary arteries. It does not directly visualize:
- noncalcified coronary plaque
- low-density noncalcified plaque
- total plaque volume throughout the coronary tree
- the coronary artery lumen well enough to determine stenosis
- the distribution and composition of plaque within individual vessels
Those limitations are inherent to the test. They do not reduce the value of CAC when the clinical question is risk stratification, but they become important when we need a more complete picture of the disease already present.
What Does a Calcium Score of Zero Really Mean?
A CAC score of zero is generally reassuring. Large population studies consistently show a substantially lower rate of cardiovascular events among people with no detectable coronary calcium compared with people who have measurable calcification. For many appropriately selected patients, that information is clinically useful.
What we do not do is translate a score of zero into a statement that the coronary arteries are normal.
Noncalcified plaque can develop before enough calcium has accumulated to appear on a CAC scan. This is one reason younger adults may occasionally have meaningful coronary plaque despite little or no measurable calcium. The same issue may arise in someone with a strong family history, significant ApoB or lipoprotein(a) elevation, diabetes, smoking exposure, metabolic disease, or other findings that suggest more cardiovascular risk than the calcium score appears to show.
Most people with CAC zero will not have severe coronary disease. Some, however, do have noncalcified plaque on CCTA, and a smaller number may have clinically important coronary narrowing.
The most accurate interpretation is that a calcium score of zero usually identifies a lower-risk group, but it does not prove the absence of coronary atherosclerosis.
What CCTA Shows That a Calcium Score Cannot
A coronary CT angiogram is performed differently. Intravenous iodinated contrast is used to visualize the lumen and walls of the coronary arteries in considerable anatomical detail.
CCTA shows whether coronary plaque is present, where it is located, and whether it is narrowing the vessel. Because the scan is not limited to calcium detection, noncalcified plaque becomes visible as well.
This is why we think of CAC primarily as a cardiovascular risk-stratification study and CCTA as an anatomical study of coronary artery disease. There is overlap between the information they provide, but they are not interchangeable tests.
What Cleerly® Adds to CCTA
A conventional CCTA is interpreted by a radiologist or cardiologist who evaluates coronary anatomy, plaque, and the degree of stenosis. Cleerly® Plaque Analysis performs additional computerized quantitative analysis of the CCTA images.
Depending on the study, the resulting analysis may include:
- total coronary plaque volume
- calcified plaque volume
- noncalcified plaque volume
- low-density noncalcified plaque
- plaque distribution within individual coronary vessels
- plaque burden in relation to vessel volume
- the location and degree of coronary stenosis
For us, one of the useful aspects of this approach is that coronary disease becomes measurable in a way that a conventional risk calculator or cholesterol result cannot provide. ApoB, LDL cholesterol, blood pressure, glucose regulation, family history, and other risk markers remain essential, but they tell us about the conditions that promote disease. CCTA allows us to examine the coronary disease that is already there.
Cleerly does not replace the physician interpreting the CCTA, and it does not predict with certainty whether a particular plaque will cause a heart attack. Its role is to provide a more standardized and quantitative description of the atherosclerosis visible on the coronary CT angiogram.
Soft Plaque, Plaque Rupture, and Why Composition Matters
Patients often hear the phrase soft plaque, which is commonly used to describe noncalcified coronary plaque. The terminology is convenient, although the underlying biology is more complicated. Noncalcified plaque can contain different proportions of lipid, fibrous tissue, and other components, and the fact that a plaque is noncalcified does not automatically mean that it is unstable.
Plaque composition nevertheless matters because many acute coronary events begin with disruption of an atherosclerotic lesion rather than the slow progression of an artery toward complete blockage. When plaque ruptures or erodes, material within the arterial wall is exposed to circulating blood. The resulting thrombus can enlarge rapidly and suddenly reduce or interrupt blood flow to the heart muscle.
The lesion involved in a heart attack is not necessarily the coronary artery's most severely narrowed plaque beforehand. CCTA research has found associations between future cardiovascular events and findings such as greater overall plaque burden, noncalcified plaque burden, low-attenuation plaque, and other adverse plaque characteristics.
This has influenced how we use coronary imaging in practice. We have seen patients whose conventional risk assessment appeared reasonably reassuring, yet CCTA demonstrated considerably more atherosclerosis than the laboratory data or calcium burden had suggested. At times the finding has been substantial enough to change treatment or prompt more immediate cardiology evaluation.
There is an important boundary to this information. Neither CCTA nor Cleerly can identify an individual plaque and reliably predict that it will rupture next week or that a heart attack is imminent. What these studies may reveal is coronary disease, plaque burden, or arterial narrowing serious enough that the patient's apparent risk changes once the anatomy is known.
Coronary Calcium Score vs. CCTA with Cleerly®
| Feature | CAC Score | CCTA with Cleerly® |
|---|---|---|
| IV contrast | No | Yes |
| Radiation | Yes, generally low dose | Yes, protocol dependent |
| Detects calcified plaque | Yes | Yes |
| Detects noncalcified plaque | No | Yes |
| Quantifies total coronary plaque | No; calcium provides an estimate of atherosclerotic burden | Yes |
| Evaluates coronary stenosis | No | Yes |
| Characterizes plaque composition | No | Yes |
| Useful for initial cardiovascular risk refinement | Yes | In selected patients |
| Quantitative assessment of plaque on follow-up imaging | Limited | Possible when repeat imaging is clinically appropriate |
Why a Rising Calcium Score Does Not Necessarily Mean Treatment Failed
Patients sometimes repeat a calcium scan after several years of lipid-lowering treatment and are understandably concerned when the score has increased. The natural assumption is that a higher score must mean that the coronary disease has worsened despite treatment.
Coronary plaque biology makes the interpretation more complicated. Statins can reduce lipid-rich components of atherosclerotic plaque while increasing plaque calcification and calcium density. Serial imaging studies have documented this transition toward more densely calcified plaque during statin treatment, a change generally interpreted as being consistent with greater plaque stability rather than increased vulnerability.
For this reason, we do not use serial calcium scores as a simple report card for lipid-lowering therapy. Once a person has established coronary disease and treatment is underway, an increase in the Agatston score does not by itself establish that treatment is failing.
When repeat coronary imaging has a genuine clinical purpose, quantitative CCTA may provide information that a repeat calcium score cannot because it allows plaque amount and composition to be examined rather than measuring calcium alone.
Where Coronary Calcium Scoring Still Fits
The availability of more sophisticated coronary imaging has not eliminated the value of calcium scoring. CAC remains one of the most practical tools for refining cardiovascular risk in appropriately selected asymptomatic adults, particularly when the decision about preventive medication remains uncertain after reviewing traditional risk factors.
There are also practical reasons to use it. No IV contrast is required, radiation exposure is generally low, the test is widely available, the prognostic evidence is extensive, and the cost is considerably lower than CCTA.
For many people, that is exactly the information needed. There is no clinical advantage in ordering a more complicated study when the simpler study answers the question at hand.
When We Use CCTA with Cleerly®
At HormoneSynergy®, we do not treat CCTA as a universal longevity screening test. We use it selectively when seeing the coronary arteries themselves is likely to improve the assessment or management of cardiovascular disease.
That may include patients whose calcium score does not appear to fit the rest of their cardiovascular picture, people with a strong family history of premature coronary disease, those with important cardiometabolic or lipid risk factors despite otherwise reassuring testing, or patients with known coronary atherosclerosis in whom more anatomical detail would influence treatment.
We also use the information differently from a stand-alone imaging service. Coronary findings are considered alongside ApoB, lipoprotein(a), blood pressure, glucose and insulin regulation, inflammatory markers, body composition, family history, medications, exercise, nutrition, sleep, smoking exposure, and the rest of the patient's preventive cardiology evaluation.
Patients with new chest pain, unexplained shortness of breath, fainting, or symptoms that may represent active coronary disease need appropriate medical evaluation. Preventive CCTA and Cleerly analysis should never delay urgent cardiovascular assessment when symptoms warrant it.
How CCTA with Cleerly® Has Changed Our Practice
One of the limitations of cardiovascular risk assessment is that people do not always behave the way a calculator predicts. A patient may exercise, maintain a healthy weight, have acceptable routine cholesterol results, and feel completely well while coronary atherosclerosis develops silently. Another person may have several risk factors yet surprisingly little detectable disease.
Laboratory testing remains essential because it helps us understand why atherosclerosis may be developing and which biological drivers are modifiable. Imaging answers another question: how much disease has already developed?
CCTA with quantitative plaque analysis has been particularly useful when those two parts of the evaluation disagree. We have seen coronary disease that was substantially more advanced than the calcium score or routine laboratory profile suggested. We have also seen studies that were reassuring enough to put other abnormal risk markers into better context.
Occasionally, the anatomy reveals a degree of plaque or coronary narrowing that warrants much more immediate attention and referral. That has changed our practice because the discussion is no longer based only on the probability that coronary disease might be present. We have anatomical evidence showing what is actually occurring within the coronary arteries.
Can Coronary Plaque Be Reduced?
The purpose of identifying coronary atherosclerosis is not simply to obtain a lower plaque measurement on the next scan. The clinical objective is to reduce myocardial infarction, stroke, cardiovascular disability, and premature death.
Effective treatment of ApoB-containing lipoproteins, hypertension, smoking, diabetes and insulin resistance, visceral adiposity, physical inactivity, and other modifiable cardiovascular risks can substantially alter the course of atherosclerotic disease. Serial coronary imaging studies have also demonstrated reductions in some forms of noncalcified plaque and changes in plaque composition during intensive lipid-lowering therapy.
We therefore discuss plaque treatment in terms of slowing progression, reducing lipid-rich and higher-risk plaque features where possible, increasing plaque stability, and lowering the patient's overall likelihood of a cardiovascular event. Some plaque components may regress. Established coronary atherosclerosis should not be presented as something that can simply be erased.
CCTA Provides More Information, but It Is Also a More Involved Test
The additional anatomical information from CCTA comes with additional considerations. The examination requires iodinated intravenous contrast and usually involves more radiation than a dedicated calcium scan, although contemporary cardiac CT protocols have reduced radiation exposure considerably.
Kidney function, previous contrast reactions, heart rate, rhythm, image quality, age, symptoms, and the reason for performing the study all matter when determining whether CCTA is appropriate. Some patients may also receive medication before or during the scan to improve coronary image quality.
The same principle applies to repeat testing. Cleerly makes quantitative comparison possible, but the ability to measure plaque again is not by itself a reason to expose someone to another CCTA. Follow-up imaging should answer a clinically useful question.
The HormoneSynergy® Preventive Cardiology Approach
Our preventive cardiology work does not begin or end with a coronary CT scan. We evaluate atherosclerotic risk from several directions because cardiovascular disease develops through the interaction of lipoproteins, blood pressure, glucose regulation, inflammation, genetics, body composition, lifestyle, aging, and other factors that vary substantially from one person to another.
ApoB helps us understand the number of atherogenic lipoprotein particles in circulation. Lipoprotein(a) identifies an important inherited source of cardiovascular risk. Blood pressure, metabolic testing, body composition, family history, smoking exposure, physical activity, sleep, and nutrition provide additional information. Depending on the patient, vascular imaging may include carotid intima-media thickness, coronary calcium scoring, or CCTA.
The choice between CAC and CCTA therefore depends on what we are trying to learn. If the clinical question is whether detectable coronary calcium would meaningfully refine cardiovascular risk, CAC may be exactly the right test. When we need to know whether coronary plaque is present, how much is there, what type of plaque it is, and whether any of it is narrowing the coronary arteries, CCTA with quantitative plaque analysis provides considerably more information.
Neither test replaces careful preventive medicine. Used for the right patient and the right question, however, coronary imaging can expose disease that might otherwise remain silent for years.
Related HormoneSynergy® Resources
Frequently Asked Questions
Does a calcium score of zero mean I have no coronary artery disease?
No. A CAC score of zero is reassuring and is associated with substantially lower cardiovascular risk, but a calcium scan cannot detect noncalcified plaque. Some people with a score of zero have coronary atherosclerosis visible on CCTA.
Is CCTA with Cleerly® better than a coronary calcium score?
CCTA provides considerably more anatomical information, but it is not automatically the better test for every patient. Calcium scoring is an established, relatively inexpensive way to refine cardiovascular risk without intravenous contrast. CCTA is more useful when seeing coronary plaque, plaque composition, or arterial narrowing is likely to change the clinical assessment.
What does Cleerly® measure?
Cleerly analyzes CCTA images to quantify and characterize coronary atherosclerosis. Depending on the study, the analysis may include total plaque volume, calcified plaque, noncalcified plaque, low-density noncalcified plaque, plaque distribution, and coronary stenosis.
Can Cleerly® tell whether a plaque is about to rupture?
No. CCTA can identify plaque characteristics associated with increased cardiovascular risk, but neither CCTA nor Cleerly can predict with certainty which individual plaque will rupture or when a cardiovascular event will occur.
Why can my calcium score rise even when cholesterol treatment is working?
Statin therapy can change the composition of atherosclerotic plaque. Imaging studies have shown reductions in lipid-rich plaque accompanied by a shift toward denser calcification. An increasing calcium score during statin treatment therefore does not automatically indicate that treatment has failed.
Can CCTA with Cleerly® be repeated to monitor plaque?
Quantitative CCTA can be compared with an earlier study when repeat imaging is clinically appropriate. Because CCTA requires intravenous contrast and involves radiation exposure, we do not view serial scanning as something that should be performed simply because the technology allows it.
Can coronary plaque regress?
Some components of coronary plaque can decrease with effective treatment, particularly lipid-rich and noncalcified plaque. Treatment may also change plaque composition in ways associated with greater stability. The broader clinical objective is to slow or stop progression and reduce the likelihood of future cardiovascular events.
Does CCTA show whether a narrowing is actually reducing blood flow?
CCTA primarily provides anatomical information about the coronary arteries and the severity of narrowing. When the physiological significance of a particular stenosis remains uncertain, additional functional assessment may sometimes be appropriate.